Pre-Conference Workshop Day

November 14, 2023

8.30am – 10.30am
Workshop A

Exploring the Capabilities of Rod Mediated Dark Adaptation for Dry AMD

  • Christine Curcio White-McKee Endowed Professor of Ophthalmology and Visual Sciences, University of Alabama at Birmingham


Being able to arrest the progression of dry AMD presents a key area to improve patient outcomes. Currently, identifying and halting the progression of dry AMD remains a substantial challenge. Join this workshop to:

  • Understand how well rod mediated dark adaption can detect intermediate dry AMD
  • Assess the ability of this approach to arrest early AMD or stabilize intermediate AMD
  • Clarify the impact of drusen deposits on rod dysfunction
  • Modify test parameters to reduce test length by incorporating AI
  • Ensure the FDA understand how the results from a rod mediated dark adaption test mean for a patients every day life

11.00AM – 1.00PM
Workshop B

Exploring Recent Developments in Functional Endpoints for Dry AMD


Solidifying accurate, reliable and reproducible functional end points remains a vitally important topic to propel the dry AMD therapeutic development forward. Attend this session to:

  • Assess how to determine functional differences
  • Ensure end point sensitivity to detect minimal lesion growth
  • Demonstrate a clear clinical significance
  • Explore how to optimize the measuring of reading speed
  • Assess how to increase the sensitivity of microperimetry
  • Strategize how to increase the use of functional end points in comparison to structural end points

1:00 pm Lunch Refreshments

2PM – 4PM
Workshop C

Comparing a Multitude of Delivery Methods for Dry AMD

  • Michael Ehrlich Executive Director Clinical Development Neurology and Ophthalmology, Alexion Pharmaceuticals


There a several delivery methods available for dry AMD therapeutics, each with their own advantages and challenges. Learn from the experts to:

  • Exploring if the intravitreal treatment burden may preclude real world sustained adoption
  • Discovering the capabilities of slow-release formulations
  • Evaluate a Systemic Approach for dry AMD Therapeutic Delivery
  • Assessing if systemic treatments may better target the disease process
  • Examine the Intricacies of the Suprachoroidal Delivery Approach
  • Optimizing the parameters for suprachoroidal delivery with microneedles such as microneedle length, pressure, and particle size